NSE: SUNPHARMA | BSE: 524715

Strong Performer, Getting Expensive

Download real time

1735.30 3.00 (0.17%)

479.2K NSE+BSE Volume

NSE 24 Feb, 2026 11:15 AM (IST)

416,356.6

Market Cap

Market Leader

Beta 1Year

Very Low volatility

Sun Pharmaceutical Industries Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SUNPHARMA, BSE:524715 Sun Pharmaceutical Industries Ltd.

Search Inside the pdf :

Sun Pharmaceutical Industries Ltd.

17 Feb 2026

1735.30

0.17%

SUN PHARMA

Buy: Sun Pharmaceutical Industr...

Target

Geojit BNP Paribas

Sun Pharma demonstrated consistent execution in key business segments, driven by robust demand for chronic therapies in India formulations, improved traction in specialty and differentiated products in the US, and stable growth in emerging markets. Furthermore, the management emphasised a continued focus on enhancing the specialty portfolio, expanding presence in complex generics and scaling up innovation-led products. Additionally, ongoing investments in research and development (R&D) and manufacturing capabilities are anticipated to support...

Geojit BNP Paribas increased Buy price target of Sun Pharmaceutical Industries Ltd. to 1899.0 on 17 Feb, 2026.

Sun Pharmaceutical Industries Ltd.

01 Feb 2026

1735.30

0.17%

Sun Pharma (BUY): All round beat; growth momentum to continue

Buy: Sun Pharmaceutical Industr...

Target

BOB Capital Markets Ltd.

Domestic sales growth driven by volume growth of 6.3% vs IPM volume growth of 1.2% due to leadership position across 14 categories

Geojit BNP Paribas increased Buy price target of Sun Pharmaceutical Industries Ltd. to 1899.0 on 17 Feb, 2026.

Sun Pharmaceutical Industries Ltd.

01 Feb 2026

1735.30

0.17%

Sun Pharma

Buy: Sun Pharmaceutical Industr...

Target

ICICI Direct

Q3FY26- Strong numbers barring the US- Revenues grew ~13% YoY to 15520 crore driven mainly by strong growth in India, global specialty portfolio, RoW and Emerging Markets. India growth was strong at 16% to 4999 crore. The US grew 6% YoY with a revenue of 4251 crore (CC term 0.6% growth) due to weakness in generics which was made good by Specialty traction to some extent and currency movements. RoW markets reported growth of ~21% to 2639 crore, mainly due to growth in both generics and specialty. Emerging markets grew ~28% to 3000 crore,...

Sun Pharmaceutical Industries Ltd. is trading above all available SMAs

Sun Pharmaceutical Industries Ltd.

31 Jan 2026

1735.30

0.17%

Innovation momentum supports growth

Buy: Sun Pharmaceutical Industr...

Target

Motilal Oswal

Sun Pharma (SUNP) posted in-line revenue (adj. for milestone income) and 6% better-than-estimated EBITDA in 3QFY26. Adj. PAT was in line with expectation.

Sun Pharmaceutical Industries Ltd. is trading above all available SMAs

Sun Pharmaceutical Industries Ltd.

07 Nov 2025

1735.30

0.17%

Steady quarter with broad-based growth and resilient margins.

Accumulate: Sun Pharmaceutical Industr...

Deven Choksey

Sun Pharma’s outlook remains strong, driven by high-margin and innovative products. India growth will be led by new launches and upcoming GLP-1 therapies, EM by branded generics, and RoW by complex products. In the U.S., momentum will be supported by LEQSELVI ramp-up, Unloxcyt launch, and continued strength in ILUMYA and CEQUA.

Sun Pharmaceutical I.. has an average target of 1935.12 from 8 brokers.

Sun Pharmaceutical Industries Ltd.

06 Nov 2025

1735.30

0.17%

Sun Pharma

Buy: Sun Pharmaceutical Industr...

Target

ICICI Direct

Q2FY26- Decent numbers despite flat US growth - Revenues grew ~9% YoY to 14478.3 crore driven mainly by growth in India, global specialty portfolio (now named as Innovative products), RoW and Emerging Markets. India growth was strong at 11% to 4735 crore. The US remained flat YoY with a revenue of 4329 crore due to weakness in generics which was made good by Innovative traction to some extent. RoW markets reported growth of ~23% to 2041 crore, mainly due to growth in both generics and specialty. Emerging markets grew ~16% to 2837 crore,...